MedPath

CEVIMELINE HYDROCHLORIDE

Cevimeline hydrochloride Capsules 30mg

Approved
Approval ID

61dd5ee1-cf89-43ea-ada4-4e4a4d9d133b

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 3, 2023

Manufacturers
FDA

Advagen Pharma Ltd

DUNS: 051627256

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

CEVIMELINE HYDROCHLORIDE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code72888-118
Application NumberANDA216682
Product Classification
M
Marketing Category
C73584
G
Generic Name
CEVIMELINE HYDROCHLORIDE
Product Specifications
Route of AdministrationORAL
Effective DateMay 3, 2023
FDA Product Classification

INGREDIENTS (11)

LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
HYDROXYPROPYL CELLULOSE, UNSPECIFIEDInactive
Code: 9XZ8H6N6OH
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
GELATIN, UNSPECIFIEDInactive
Code: 2G86QN327L
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
SHELLACInactive
Code: 46N107B71O
Classification: IACT
SODIUM LAURYL SULFATEInactive
Code: 368GB5141J
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT
FERROSOFERRIC OXIDEInactive
Code: XM0M87F357
Classification: IACT
POTASSIUM HYDROXIDEInactive
Code: WZH3C48M4T
Classification: IACT
CEVIMELINE HYDROCHLORIDEActive
Quantity: 30 mg in 1 1
Code: P81Q6V85NP
Classification: ACTIR

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CEVIMELINE HYDROCHLORIDE - FDA Drug Approval Details